Notice2024-23591
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 11, 2024
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 198 (Friday, October 11, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 198 (Friday, October 11, 2024)]
[Notices]
[Page 82631]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-23591]
[[Page 82631]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Rapid Response Partnership Vehicle
Notice is hereby given that, on July 11, 2024, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Rapid Response Partnership
Vehicle (``RRPV'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Esperovax, Inc., Plymouth, MI; Genomic Expression,
Inc., Beverly, MA; ID Biologics, Inc., Nashville, TN; MPS Medical,
Inc., Brea, CA; QuidelOrtho Corp., San Diego, CA; Sinergium Biotech
S.A., Buenos Aires, ARGENTINA; Somatek, San Diego, CA; True
Diagnostics, Inc., Carlsbad, CA; VaxSyna, Inc., Franklin, NH; Burrell
International Group LLC, Washington, DC; Cellular Technology, Ltd.,
Shaker, OH; QIAGEN LLC, Germantown, MD; RAIsonance, Inc., Greenwood
Village, CO; Canaria Technologies Pty, Ltd., Brisbane, AUSTRALIA;
Elarex, Inc., Burlington, CANADA; Gila Diagnostics, Inc., Phoenix, AZ;
IIT Research Institute, Chicago, IL; ImmunoServ, Cardiff, UNITED
KINGDOM; OraSure Technologies, Inc., Bethlehem, PA; Vaccine Company,
Inc., Bethesda, MD; Visby Medical, Inc., San Jose, CA; Global Life
Science Solutions USA LLC dba Cytiva, Marlborough, MA; Pathway Policy
Group LLC, McLean, VA; PSC Biotech Corporation, Pomona, CA; Q-VANT
Biosciences, Inc., Forestdale, MA; Seqirus, Inc., Holly Springs, NC;
The Rector and Visitors of the University of Virginia, Charlottesville,
VA; Gusmer Enterprises, Inc., Mountainside, NJ; Azure Medical, Inc., La
Verne, CA; Cellphire Therapeutics, Inc., Rockville, MD; CorDx, Inc.,
San Diego, CA; The University of Central Florida Board of Trustees,
Orlando, FL; The Albert B. Sabin Vaccine Institute, Inc., Washington,
DC; InFlo Medical, Irvine, CA; Shionogi, Inc., Florham Park, NJ; Agno
Pharmaceuticals LLC, Bethlehem, PA; Astute Crew LLC, San Lorenzo, CA;
CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Cornerstone Government
Affairs, Inc., Washington, DC; Cytophage Technologies, Inc., Winnipeg,
CANADA; Decoy Therapeutics, Cambridge, MD; Emergex USA Corp.,
Doylestown, PA; Emergo Therapeutics, Chapel Hill, NC; GE Medical
Systems Information Technologies, Inc. dba GE Healthcare Technology &
Innovation Center, Niskayuna, NY; GRI Technology Solutions LLC, San
Mateo, CA; Humanetics Corp., Minneapolis, MN; North X Biologics AB,
Matfors, SWEDEN; Novavax, Inc., Gaithersburg, MD; Photosynthetic B.V.,
Amsterdam, NETHERLANDS; Pioneer Vaccine, Inc., Daejeon, REPUBLIC OF
KOREA; Quantiscope PBC, Salt Lake City, UT; Validated Cloud, Inc.,
Waltham, MA; Vivaldi Biosciences, Inc., Fort Collins, CO; Wheeler Bio,
Inc., Oklahoma, OK; A-Alpha Bio, Inc., Seattle, WA; Prosetta
Biosciences, Inc., San Francisco, CA; Revagenix, Inc., San Francisco,
CA; University of Texas Medical Branch at Galveston, Galveston, TX;
AlbaNY labs LLC, Rensselaer, NY; AI Proteins, Inc., Boston, MA; Appel
Sauce Studios LLC, Menlo Park, CA; Microbiologics, Inc., Saint Cloud,
MN; POP Biotechnologies, Buffalo, NY; Southern Research Institute,
Birmingham, AL; and SPOC Proteomics, Inc., Scottdale, AZ, have been
added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and RRPV intends to file additional
written notifications disclosing all changes in membership.
On January 05, 2024, RRPV filed its original notification pursuant
to section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to section 6(b) of the Act on
April 16, 2024 (89 FR 26928).
The last notification was filed with the Department on April 12,
2024. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on June 21, 2024 (89 FR 52095).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-23591 Filed 10-10-24; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on October 11, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.